Welcome to our dedicated page for Editas Medicine news (Ticker: EDIT), a resource for investors and traders seeking the latest updates and insights on Editas Medicine stock.
Editas Medicine Inc (NASDAQ: EDIT), a leader in CRISPR-based genome editing, provides this centralized hub for tracking all corporate developments and scientific advancements. Access real-time updates on clinical trial progress, regulatory milestones, and financial disclosures essential for monitoring this pioneering biotech firm.
This resource aggregates EDIT's press releases, partnership announcements, and peer-reviewed research findings. Investors will find critical updates on pipeline therapies for genetic disorders, while analysts gain insights into strategic initiatives shaping the genomic medicine landscape. Content spans quarterly earnings, intellectual property developments, and preclinical breakthroughs.
Key categories include therapy authorization updates, collaboration agreements with research institutions, and presentations at major medical conferences. All materials are sourced directly from Editas Medicine and verified financial filings to ensure reliability.
Bookmark this page for efficient tracking of EDIT's progress in developing CRISPR/Cas9 and Cas12a therapies. Check regularly for authoritative updates on one of biotech's most innovative gene-editing platforms.
Editas Medicine announced promising preclinical data for EDIT-301, an innovative autologous cell therapy targeting sickle cell disease and beta-thalassemia. Utilizing CRISPR/Cas12a technology, the therapy demonstrated high gene editing efficiency and significant fetal hemoglobin induction in clinical studies. The company successfully developed a scalable manufacturing process, showing consistent, robust results in animal models. Editas plans to file an IND for EDIT-301 by the end of 2020, aiming to enter a Phase 1/2 clinical trial, potentially offering a transformative solution for patients.
Editas Medicine (Nasdaq: EDIT) has granted inducement awards to Lisa Michaels, M.D., the newly appointed Executive Vice President and Chief Medical Officer. The Board approved a stock option grant for up to 120,000 shares at $30.41 per share, which vests over four years. Additionally, Dr. Michaels received a restricted stock unit award for 20,000 shares, vesting at 25% annually over four years. These awards comply with Nasdaq Listing Rule 5635(c)(4) and are contingent on her continued employment with Editas Medicine.
Editas Medicine, a prominent genome editing company, announced its participation in the Barclays Gene Editing & Gene Therapy Summit on November 16, 2020, at 10:15 AM ET. The presentation will be webcast live on their website, with archived recordings available for 30 days post-event.
Editas focuses on utilizing CRISPR technologies to develop precise genomic medicines aimed at treating serious diseases globally.
Editas Medicine has appointed Lisa A. Michaels, M.D. as its new Executive Vice President and Chief Medical Officer. Dr. Michaels brings over 25 years of experience in clinical research and drug development from her previous role at Bayer Pharmaceuticals. She will oversee clinical research and drug development for Editas' pipeline, notably focusing on EDIT-301 for sickle cell disease. The company recently reacquired rights to its ocular pipeline, enhancing its position in the genome editing landscape.
Editas Medicine announced key developments in its third quarter 2020 financial results. The company has completed dosing for the adult low-dose cohort in the EDIT-101 BRILLIANCE trial and regained full control of its ocular programs through a new agreement with AbbVie. Cash and marketable securities stood at $541 million as of September 30, 2020. EDIT-301 for sickle cell disease is on track for an IND filing by year-end, while EDIT-201's preclinical data will be shared at upcoming conferences. The company reported a net income of $7.8 million in Q3 compared to a net loss of $32.9 million last year.
Editas Medicine, a leading genome editing company, announced a conference call and webcast on November 5, 2020, at 5:00 PM ET to discuss its third-quarter results and corporate updates. Investors can access the call by dialing (844) 348-3801 domestically or (213) 358-0955 internationally. The conference ID is 9992536. A live webcast will be available on the Editas Medicine website.
Editas focuses on developing transformative genomic medicines using CRISPR technology.
On October 1, 2020, Editas Medicine (Nasdaq: EDIT) announced its participation in the Chardan Virtual 4th Annual Genetic Medicines Conference, scheduled for October 5, 2020, at 10:30 a.m. ET. The event will feature a fireside chat and will be webcast live on the company's website, with archived recordings available for 30 days post-event. Editas Medicine focuses on developing transformative genomic medicines using CRISPR technology to treat serious diseases. For more updates, visit www.editasmedicine.com.
Editas Medicine, Inc. (Nasdaq: EDIT) announced that the U.S. Patent and Trademark Office has granted Broad Institute’s motion for priority in a patent interference case. This decision denies priority to CVC, meaning Broad is now the 'Senior Party.' Editas remains confident in its exclusive licenses for foundational CRISPR/Cas9 patents. Broad’s patents are valid in multiple jurisdictions, including the U.S., and Editas aims to leverage these innovations in developing treatments for serious diseases.
Editas Medicine, a leading genome editing company, will participate in several upcoming investor conferences. Key events include Citi’s 15th Annual BioPharma Virtual Conference on September 9, 2020, at 3:20 p.m. ET, a fireside chat at the Wells Fargo 2020 Virtual Healthcare Conference on September 10, 2020, at 10:40 a.m. ET, and another fireside chat at the Morgan Stanley 18th Annual Global Healthcare Conference on September 15, 2020, at 10:15 a.m. ET. These events will be webcast live on the company’s website, with recordings available for 30 days afterwards.
Editas Medicine has regained full control of ocular medicines with a new agreement with AbbVie. The company is on track to dose patients in the BRILLIANCE trial for EDIT-101 by the end of 2020, and plans to file an IND for EDIT-301 for sickle cell disease. A recent equity offering raised $216 million, strengthening its balance sheet, which now holds $599 million in cash as of June 30, 2020. The company reported a net loss of $23.6 million for Q2 2020, an improvement from $33.8 million in Q2 2019, with an increase in collaboration revenues to $10.7 million.
FAQ
What is the current stock price of Editas Medicine (EDIT)?
What is the market cap of Editas Medicine (EDIT)?
